Castilla, J. (Jesús)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
7 results
Search Results
Now showing 1 - 7 of 7
- Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 midseason analysis(European Centre for Disease Prevention and Control, 2017) Martínez-Baz, I. (Iván); Navascués, A. (Ana); Fernandino, L. (L.); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Perez-Garcia, A. (A.); Pozo, F. (Francisco); Casado-Redín, I. (Iñaki); Ezpeleta, C. (Carmen); Díaz-González, J. (J.)The 2016/17 mid-season vaccine effectiveness esti- mate against influenza A(H3N2) was 15% (95% con- fidence interval: -11 to 35) in Navarre. Comparing to individuals unvaccinated in the current and four prior seasons, effectiveness was 24% for current and 3-4 prior doses, 61% for current and 1-2 prior doses, 42% for only current vaccination, and 58% for 3-4 prior doses. This suggests moderate effectiveness for dif- ferent combinations of vaccination in the current and prior seasons.
- Caracterización de la pandemia de gripe A H1N1 2009 en Navarra(2010) Elía Pitillas, F. (Fernando); Red de Médicos Centinela y Red de VigilanciaEpidemiológica y Microbiológica de la gripe de Navarra; Morán, J. (J.); Martinez-de-Artola, V. (Víctor); Fernández-Alonso, M. (Miriam); Zamora, M.J. (M.J.); Salcedo-Garayalde, E. (Esther); Fernández, C. (C.); Mazón-Ramos, A. (Ana); Castilla, J. (Jesús); Reina, G. (Gabriel); García-Cenoz, M. (Manuel); Irisarri, F. (Fátima); Barricarte, A. (Aurelio)Fundamento. Describir la actividad gripal durante la pandemia de 2009-2010 en Navarra y compararla con la de temporadas anteriores. Métodos. Se han analizado los casos de gripe notificados en atención primaria y todas las confirmaciones virológicas realizadas en pacientes de atención primaria y en hospitales de Navarra entre las semanas 21 de 2009 y 20 de 2010. Resultados. El virus de la gripe A (H1N1) 2009 se detectó en Navarra entre las semana 23 de 2009 a la 2 de 2010, periodo en el que se registraron 39 casos con diagnóstico médico de síndrome gripal por 1.000 habitantes. El umbral epidémico se superó en dos periodos, con un pico en julio y otro mayor en noviembre. La mayor incidencia se alcanzó en niños de 5 a 14 años (121 por mil), seguidos por el grupo de menores de 5 años. Se produjeron 224 hospitalizaciones (36 por 100.000 habitantes) con confirmación de gripe A H1N1 2009, 8% de ellos requirieron ingreso en unidades de cuidados intensivos y hubo cuatro defunciones (0,6 por 100.000 habitantes). La tasa de hospitalizaciones fue mayor en niños menores de 5 años (163 por 100.000 habitantes), mientras que la probabilidad de derivación a cuidados intensivos aumentó con la edad. Conclusión. A pesar de no haber dispuesto de una vacuna específica hasta que la temporada estaba muy avanzada, el virus de gripe A (H1N1) 2009 produjo una onda gripal en rangos similares a los de otras temporadas y su repercusión en hospitalizaciones y casos graves fue moderada.
- Respiratory syncytial virus hospitalization in children in northern Spain(Public Library of Science, 2018) Moreno-Galarraga, L. (Laura); Martínez-Baz, I. (Iván); Sierrasesumaga, L. (Luis); Viguria, N. (Natividad); Castilla, J. (Jesús); Salcedo, B. (Blanca)Objectives: Understanding respiratory syncytial virus (RSV) morbidity may help to plan health care and future vaccine recommendations. We aim to describe the characteristics and temporal distribution of children diagnosed with RSV admitted in a Spanish hospital. Methods: Descriptive study for which the hospital discharges of children < 5 years of age with RSV infection were analyzed. The information was extracted from the hospital discharge database of a reference pediatric hospital in northern Spain for the 2010-2011 to 2014-2015 RSV seasons. Results: Six hundred and forty-seven hospitalizations of children with RSV infection were analyzed, 94% of which occurred between the second week of November and the last week of March. Most children (72%) were under one year of age and 95% were previously healthy infants. Infants born from October to December had the highest risk of hospitalization in the first year of life. The median length of hospital stay of children with and without comorbidities was six and three days, respectively. 6.5% of the hospitalized cases were admitted to the pediatric intensive care unit; this percentage was higher among children < 2 months (adjusted odds ratio 4.15; 95% confidence interval: 1.37-12.61) or with comorbidities (adjusted odds ratio 4.15; 95% confidence interval: 1.53-11.28). The case lethality was 0.3%. Conclusions: The risk of hospitalizations for RSV is high during the first year of life and increases among infants born in the fall. Being under two months of age and presenting comorbidities are the main risk factors associated to pediatric intensive care unit admission.
- Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus(Elsevier, 2019) Navascués, A. (Ana); Pérez-García, A. (Alejandra); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Ezpeleta, C. (Carmen)Introduction: New efficient strategies are needed for the assessment of active hepatitis C virus (HCV) infection. The aim of this study was to evaluate the ability of HCV core antigen (HCV-cAg) as a marker of active HCV infection in newly diagnosed patients, for treatment monitoring, and for the detection of therapeutic failure. Materials and methods: A prospective study was conducted at a regional reference hospital in Spain. HCV- cAg and viral load (RNA-HCV) were tested in plasma or serum samples from three patient groups: new diagnosis, treatment monitoring, and treatment failure. The treatment monitoring group was tested at the beginning of treatment, at 4 weeks post-initiation, at the end of treatment, and at 12 weeks post- treatment completion. The Architect HCV core antigen assay was performed for HCV-cAg testing, and viral load was quantified with the Cobas 6800 system. Results: A total of 303 samples from 124 patients were analyzed. Excellent correlation was seen between HCV-cAg and HCV-RNA (R2 = 0.932). The optimal cut-off value was 3 fmol/l in the receiver operating characteristics curve analysis, and the area under the curve was 0.987 (95% confidence interval 0.972– 1.000). HCV-cAg sensitivity and specificity were 97% and 95%, respectively. Most diverging results were observed in the treatment follow-up group. Conclusions: HCV-cAg demonstrated good sensitivity and specificity as a marker for active HCV infection, new diagnosis, detection of antiviral therapeutic failure, and treatment monitoring.
- Interim efecctiveness of trivalen influenza vaccine in a Seaton dominated by lineage mismatched influenza B, northern Spain, 2017/18.(Eurosurveillance, 2018) Martínez-Baz, I. (Iván); Navascués, A. (Ana); Pérez-García, A. (Alejandra); Ezpeleta, G. (Guillermo); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Pozo, F. (Francisco); Casado, I. (Itziar); Ezpeleta, C. (Carmen)The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
- Progress in the elimination of hepatitis C virus infection in Spain: a population-based cohort study(Public Library of Science, 2018) San-Miguel, R. (Ramon); Martínez-Baz, I. (Iván); Pérez-García, A. (Alejandra); Burgui, C. (Cristina); Goñi-Esarte, S. (Silvia); Repáraz, J. (Jesús); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Juanbeltz, R. (Regina); Casado, I. (Itziar); Ezpeleta, C. (Carmen); Zozaya, J.M. (José Manuel)Background: The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain. Methods: Using electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this period. Results: At the beginning of 2015 there were 1503 patients diagnosed with positive HCV-RNA, 2.4 per 1000 inhabitants, and at the end of 2017 the prevalence had decreased by 47%. In the study period, 333 (18 per 100,000 person-years) new positive HCV-RNA cases were detected, but only 76 (23%; 4.2 per 100,000 person-years) did not have anti-HCV antibodies previously detected. Prevalent cases and new diagnoses of active infection were more frequent in men, people born in 1950-1979, HIV-infected patients and in those with lower income levels. Among patients with HCV-RNA, 984 achieved PTVC (22.7 per 100 person-years). PTVC was less frequent in patients born before 1940, in immigrants and in patients with lower income levels. Conclusions: The prevalence of diagnosed active HCV infection has dropped by almost half over three years, because the number of patients with PTVC was much higher than the number of new diagnoses. Interventions specifically targeted at population groups with less favourable trends may be necessary.
- Detection of Respiratory Viruses in Deceased Persons, Spain, 2017(Centers for Disease Control and Prevention, 2018) Martínez-Baz, I. (Iván); Navascués, A. (Ana); Pérez-García, A. (Alejandra); Aguinaga, A. (Aitziber); Castilla, J. (Jesús); Floristan-Floristan, M.Y. (María Yugo); Casado, I. (Itziar); Ezpeleta, C. (Carmen)During the 2016–17 influenza season in Spain, we tested specimens from 57 elderly deceased persons for respira- tory viruses. Influenza viruses were detected in 18% of the specimens and any respiratory virus in 47%. Only 7% of participants had received a diagnosis of infection with the detected virus before death.